Lifshitz Law PLLC Announces Investigations of Apollo Global Management, Inc. (NYSE:APO), Aquestive Therapeutics, Inc. (NASDAQ:AQST), Boston Scientific (NYSE:BSX), and Eos Energy Enterprises, Inc. (NASDAQ:EOSE)

NEW YORK CITY, NY / ACCESS Newswire / May 27, 2026 / Lifshitz Law Firm

Apollo Global Management, Inc. (NYSE:APO)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's leadership figures, including Marc Rowan and Leon Black, frequently communicated with Jeffrey Epstein in the 2010s regarding the Company's business; (ii) as a result, the Company's assertion that Apollo Global had never done business with Jeffrey Epstein was untrue; (iii) because of the entanglement between Apollo Global's leaders and Jeffrey Epstein, the harm to the Company's reputation was more than a mere possibility; and (iv) as a result, the Company's statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

If you are an APO investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) the timeline for approval and launch of Aquestive's New Drug Application ("NDA") for Anaphylm (dibutepinephrine) sublingual film was materially overstated; (ii) the Company's statements expressing confidence in the NDA submission and their repeated assertions that Anaphylm would receive approval by the Prescription Drug User Fee Act date of January 31, 2026 lacked a reasonable basis; (iii) the NDA faced significant risks related to human factors associated with the use of the sublingual film, including packaging, administration, use, and labeling; and (iv) the Company concealed or minimized the material impact of these human‑factors issues on the likelihood and timing of regulatory approval.

If you are an AQST investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Boston Scientific (NYSE:BSX)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) Boston Scientific's U.S. EP segment's growth rate was unsustainable and was approaching an earlier tipping point than the market was anticipating; (ii) the Company was experiencing new competition entrants that were sapping Boston Scientific's U.S. Electrophysiology market share and thus limiting the Company's growth potential; (iii) as a result, the Company's repeated statements of confidence in the U.S. EP division's growth trajectory, including repeatedly elevated full-year guidance metrics, were materially misleading; and (iv) as a result, the Company's positive statements about Boston Scientific's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you are a BSX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Eos Energy Enterprises, Inc. (NASDAQ:EOSE)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Eos Energy was unable to achieve the ramp in production and capacity utilization required to achieve its previously set guidance; (ii) Eos Energy's battery line downtime was running well above industry norms, the design intent of the line, and internal forecasts; (iii) Eos Energy was experiencing delays in the ability for its automated bipolar production to hit quality targets; (iv) Eos Energy's inadequate systems and processes prevented it from ensuring reasonably accurate guidance and that its public disclosures were timely, accurate, and complete; and (v) as a result of the foregoing, the Company's positive statements about Eos Energy's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you are an EOSE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

ATTORNEY ADVERTISING.© 2026 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516) 493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.

Lifshitz Law PLLC

Phone: 516-493-9780

Facsimile: 516-280-7376

Email: [email protected]

SOURCE: Lifshitz Law Firm